Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TGTX

TG Therapeutics Inc

Apr 28 • 04:00PM ET

34.58

-0.80 -2.26 %

Healthcare • Biotechnology • USA • Mid • NASD

Peers: BLUE GILD RARE JAZZ NBIX SRPT AKBA PTCT AUPH XOMA

| Held by: IJR VTI XBI IWM VB VBK VXF SPSM IJT IWO

Scroll to Statements

Index	RUT	P/E	12.45	EPS (ttm)	2.78	Insider Own	7.23%	Shs Outstand	155.31M	Perf Week	-4.69%
Market Cap	5.52B	Forward P/E	15.41	EPS next Y	2.24	Insider Trans	-0.04%	Shs Float	148.14M	Perf Month	8.91%
Enterprise Value	5.63B	PEG	102.73	EPS next Q	0.28	Inst Own	65.41%	Short Float	19.39%	Perf Quarter	12.27%
Income	447.18M	P/S	8.96	EPS this Y	-51.84%	Inst Trans	1.98%	Short Ratio	15.36	Perf Half Y	3.73%
Sales	616.29M	P/B	8.29	EPS next Y	68.20%	ROA	54.50%	Short Interest	28.73M	Perf YTD	16.00%
Book/sh	4.17	P/C	38.90	EPS next 5Y	0.15%	ROE	102.75%	52W High	46.48 -25.60%	Perf Year	-17.73%
Cash/sh	0.89	P/FCF	-	EPS past 3/5Y	- -	ROIC	49.65%	52W Low	25.28 36.79%	Perf 3Y	39.27%
Dividend Est.	-	EV/EBITDA	44.95	Sales past 3/5Y	504.86% 426.73%	Gross Margin	83.66%	Volatility	4.65% 3.68%	Perf 5Y	-20.71%
Dividend TTM	-	EV/Sales	9.14	EPS Y/Y TTM	1802.16%	Oper. Margin	20.01%	ATR (14)	1.38	Perf 10Y	267.09%
Dividend Ex-Date	-	Quick Ratio	3.29	Sales Y/Y TTM	87.32%	Profit Margin	72.56%	RSI (14)	52.20	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	4.10	EPS Q/Q	-0.69%	SMA20	-0.86%	Beta	1.73	Target Price	44.57
Payout	0.00%	Debt/Eq	0.39	Sales Q/Q	78.00%	SMA50	8.59%	Rel Volume	1.21	Prev Close	35.38
Employees	399	LT Debt/Eq	0.39	Earnings	Feb 26 BMO	SMA200	8.27%	Avg Volume	1.87M	Price	34.58
IPO	Dec 14, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	-60.28% 0.41%	Trades		Volume	2,271,871	Change	-2.26%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-06-25	Resumed	H.C. Wainwright	Buy	$60
Jul-10-25	Resumed	Goldman	Neutral	$37
Oct-29-24	Initiated	TD Cowen	Buy	$50
Aug-02-23	Upgrade	Goldman	Sell → Neutral	$16 → $12
Jun-26-23	Resumed	Jefferies	Buy	$55 → $40
May-20-22	Initiated	BofA Securities	Underperform	$5
Feb-23-22	Reiterated	B. Riley Securities	Buy	$49 → $35
Nov-15-21	Downgrade	Goldman	Neutral → Sell	$33 → $26
Apr-20-21	Initiated	Goldman	Neutral	$50
Apr-19-21	Reiterated	H.C. Wainwright	Buy	$79 → $89
Sep-01-20	Initiated	JP Morgan	Overweight	$38
Aug-11-20	Reiterated	H.C. Wainwright	Buy	$32 → $38
Jun-05-20	Initiated	Evercore ISI	Outperform	$60
Jan-17-20	Reiterated	H.C. Wainwright	Buy	$20 → $24
Nov-27-19	Resumed	B. Riley FBR	Buy	$12
Feb-06-19	Resumed	Jefferies	Buy	$8
Sep-25-18	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-18	Reiterated	B. Riley FBR, Inc.	Buy	$21.50 → $27
Dec-01-17	Resumed	B. Riley FBR, Inc.	Buy	$21.50
Nov-14-17	Resumed	H.C. Wainwright	Buy	$33

Show Previous Ratings

Apr-22-26 07:30AM	TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting (GlobeNewswire) +5.60%
Apr-16-26 05:52AM	TG Therapeutics concludes enrolment in Phase III Briumvi trial (Clinical Trials Arena)
Apr-15-26 07:30AM	TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI (GlobeNewswire)
Mar-19-26 07:30AM	TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million (GlobeNewswire)
Mar-12-26 07:00AM	Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update (Business Wire)
08:03AM	Loading…
Mar-10-26 08:03AM	BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) (Insider Monkey)
Mar-09-26 07:30AM	Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI in People with Highly Active Relapsing Multiple Sclerosis (GlobeNewswire)
Mar-08-26 06:25AM	Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings (Insider Monkey)
Mar-06-26 07:30AM	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting (GlobeNewswire)
Mar-02-26 07:01AM	Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis (Business Wire)
Mar-01-26 04:27AM	TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 (Insider Monkey)
Feb-27-26 12:08PM	TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line (Zacks)
08:45AM	TG Therapeutics Q4 Earnings Call Highlights (MarketBeat)
Feb-26-26 04:11PM	TG Therapeutics Inc (TGTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
09:55AM	TG Therapeutics (TGTX) Misses Q4 Earnings Estimates (Zacks)
08:30AM	Loading…
08:30AM	TG Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
07:12AM	TG Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance (GlobeNewswire)
Feb-25-26 12:15PM	Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-23-26 10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
07:30AM	TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update (GlobeNewswire)
Feb-17-26 07:30AM	Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis (GlobeNewswire)
Feb-11-26 03:14PM	Goldman Sachs Raises TG Therapeutics, Inc. (TGTX) Target to $39 on 2026 Guidance (Insider Monkey)
Feb-08-26 04:17PM	TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis (GlobeNewswire)
Feb-07-26 03:33AM	TG Therapeutics (TGTX) Sees Price Target Drop from JPMorgan (Insider Monkey)
Feb-06-26 07:30AM	TG Therapeutics Announces Presentation of Data for BRIUMVI (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum (GlobeNewswire)
Jan-27-26 07:30AM	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum (GlobeNewswire)
Jan-15-26 10:31AM	These under-the-radar stocks combine fast growth with big upside potential (MarketWatch)
Jan-14-26 04:39PM	Stock Indexes Settle Lower on Tech Weakness (Barchart) +5.99%
10:52AM	TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results (Zacks)
09:45AM	Loading…
09:45AM	Stocks to Watch Wednesday: Netflix, Bank of America, Wells Fargo (The Wall Street Journal)
09:25AM	Why TG Therapeutics Stock Is Moving Today (Benzinga)
05:03AM	Stock Market Today: Dow Jones, Nasdaq 100 Futures Tumble Ahead Of Supreme Court Ruling On Trump's Tariffs-Wells Fargo, BP, WeRide In Focus (Benzinga)
Jan-13-26 05:05PM	TG Therapeutics Stock Climbs After The Bell: Here's Why (Benzinga)
04:25PM	TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones (GlobeNewswire)
Jan-07-26 07:30AM	TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-25 08:32AM	Is the Options Market Predicting a Spike in TG Therapeutics Stock? (Zacks)
Nov-28-25 07:30AM	TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-19-25 08:30AM	TG Therapeutics Makes 2025 Deloitte Technology Fast 500 List of America's Fastest-Growing Companies (GlobeNewswire)
Nov-10-25 04:00PM	TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit (GlobeNewswire) -6.02%
12:01PM	TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results (Investor's Business Daily)
Nov-05-25 09:45AM	Why TG Therapeutics (TGTX) is a Top Growth Stock for the Long-Term (Zacks)
Nov-04-25 10:26AM	TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised (Zacks)
Nov-03-25 04:25PM	Highly Watched TG Therapeutics Smashes Profit Views But There's A Caveat (Investor's Business Daily)
04:00PM	TG Therapeutics Inc (TGTX) Q3 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ... (GuruFocus.com)
08:53AM	Highly Watched TG Therapeutics Smashes Profit Views - With A Caveat (Investor's Business Daily)
07:09AM	TG Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance (GlobeNewswire)
Oct-31-25 07:30AM	TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Oct-28-25 05:55PM	Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
10:00AM	Earnings Preview: Amgen (AMGN) Q3 Earnings Expected to Decline (Zacks)
07:30AM	TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI (GlobeNewswire)
Oct-27-25 10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks)
Sep-25-25 06:24AM	Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength? (Zacks)
Sep-24-25 09:10AM	New Data for BRIUMVI Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment (GlobeNewswire)
Sep-10-25 07:30AM	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting (GlobeNewswire)
Sep-08-25 07:30AM	TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment (GlobeNewswire)
Sep-04-25 07:30AM	TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Sep-03-25 12:40PM	TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback (Benzinga) +6.66%
11:30AM	Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report? (Zacks)
07:30AM	TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program (GlobeNewswire)
Aug-28-25 08:00AM	TG Therapeutics to Participate in the Cantor Global Healthcare Conference (GlobeNewswire)
Aug-05-25 01:06PM	TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance (Insider Monkey)
12:12PM	TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line (Zacks)
09:30AM	Company News for Aug 5, 2025 (Zacks)
03:00AM	TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
Aug-04-25 01:14PM	Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide (Benzinga) -17.99%
11:29AM	Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook (Investor's Business Daily)
08:10AM	TG Therapeutics (TGTX) Misses Q2 Earnings Estimates (Zacks)
07:04AM	TG Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance (GlobeNewswire)
Jul-30-25 10:00AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:30AM	TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Jul-29-25 10:24AM	Analysts Hike Profit Targets On This Gold Stock, Defense Name (Investor's Business Daily)
10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
Jul-17-25 02:05PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily)
Jul-15-25 01:08PM	Liquidia Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Jul-10-25 02:24PM	Arcutis Biotherapeutics Stock Scores RS Rating Upgrade (Investor's Business Daily)
Jul-02-25 12:05PM	Jim Cramer on TG Therapeutics: "You Should Buy the Stock" (Insider Monkey)
Jun-30-25 09:22PM	Lightning Round: Buy anything uranium, says Jim Cramer (CNBC TV)
Jun-16-25 09:47AM	Are Options Traders Betting on a Big Move in TG Therapeutics Stock? (Zacks)
Jun-06-25 07:30AM	TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
Jun-02-25 08:00AM	TG Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-30-25 07:30AM	TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting (GlobeNewswire)
May-27-25 07:30AM	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting (GlobeNewswire)
May-19-25 06:20AM	Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar? (Zacks)
May-09-25 10:28AM	TG Therapeutics, Inc. (TGTX): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
May-06-25 03:03AM	TG Therapeutics Inc (TGTX) Q1 2025 Earnings Call Highlights: Strong BRIUMVI Sales and Increased ... (GuruFocus.com) -7.48%
May-05-25 11:20PM	Q1 2025 TG Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -13.26%
03:37PM	Why TG Therapeutics Stock Was Tumbling Today (Motley Fool)
01:30PM	TG Therapeutics: Share Price Slip On Q1 Earnings Unsurprising Given Challenges (Seeking Alpha)
10:55AM	TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:10AM	TG Therapeutics (TGTX) Lags Q1 Earnings Estimates (Zacks)
07:08AM	TG Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance (GlobeNewswire)
May-01-25 09:20AM	Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-30-25 10:01AM	TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth (Zacks)
07:30AM	TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Apr-28-25 06:20AM	Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now? (Zacks)
Apr-23-25 06:06PM	BBSC: Lagging Several Small-Cap Core ETFs (Seeking Alpha)

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Echelard Yann	Director	Nov 24 '25	Sale	32.57	5,000	162,850	223,816	Nov 25 05:31 PM
Echelard Yann	Director	Nov 24 '25	Proposed Sale	32.57	5,000	162,850		Nov 24 04:04 PM
Lonial Sagar	Director	Sep 11 '25	Sale	32.24	20,852	672,268	94,061	Sep 12 04:42 PM
Lonial Sagar	Director	Sep 11 '25	Proposed Sale	32.24	20,852	672,233		Sep 11 04:55 PM
Echelard Yann	Director	Jun 13 '25	Sale	36.94	10,000	369,400	228,816	Jun 16 05:47 PM
Echelard Yann	Director	Jun 13 '25	Proposed Sale	36.93	10,000	369,348		Jun 13 12:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TGTX

TG Therapeutics Inc

Upgrade your Finviz experience